United Therapeutics Corporation

Symbol: UTHR

NASDAQ

266.05

USD

Market price today

  • 11.9032

    P/E Ratio

  • -0.1012

    PEG Ratio

  • 11.80B

    MRK Cap

  • 0.00%

    DIV Yield

United Therapeutics Corporation (UTHR) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.89%

Operating Profit Margin

0.50%

Net Profit Margin

0.42%

Return on Assets

0.16%

Return on Equity

0.19%

Return on Capital Employed

0.22%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Full-time employees:1168
City:Silver Spring
Address:1040 Spring Street
IPO:1999-06-17
CIK:0001082554

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

General Outlook

When we look at how much money they make before expenses, they keep 0.889% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.503%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.420%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.162% return, is a testament to United Therapeutics Corporation's adeptness in optimizing resource deployment. United Therapeutics Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.187%. Furthermore, the proficiency of United Therapeutics Corporation in capital utilization is underscored by a remarkable 0.223% return on capital employed.

Stock Prices

United Therapeutics Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $258.48, while its low point bottomed out at $236.65. This variance in figures offers investors a lucid insight into the roller-coaster ride that is United Therapeutics Corporation's stock market.

Liquidity Ratios

Analyzing UTHR liquidity ratios reveals its financial health of the firm. The current ratio of 377.49% gauges short-term asset coverage for liabilities. The quick ratio (350.35%) assesses immediate liquidity, while the cash ratio (145.42%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio377.49%
Quick Ratio350.35%
Cash Ratio145.42%

Profitability Ratios

UTHR profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 55.28% underscores its earnings before tax deductions. The effective tax rate stands at 23.93%, revealing its tax efficiency. The net income per EBT, 76.07%, and the EBT per EBIT, 109.88%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 50.31%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin55.28%
Effective Tax Rate23.93%
Net Income per EBT76.07%
EBT per EBIT109.88%
EBIT per Revenue50.31%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.77, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 812.98% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding350
Days of Inventory Outstanding158
Operating Cycle202.66
Days of Payables Outstanding400
Cash Conversion Cycle-198
Receivables Turnover8.13
Payables Turnover0.91
Inventory Turnover2.31
Fixed Asset Turnover2.33
Asset Turnover0.38

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 20.84, and free cash flow per share, 16.01, depict cash generation on a per-share basis. The cash per share value, 57.61, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.39, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share20.84
Free Cash Flow per Share16.01
Cash per Share57.61
Operating Cash Flow Sales Ratio0.39
Free Cash Flow to Operating Cash Flow Ratio0.77
Cash Flow Coverage Ratio1.63
Short Term Coverage Ratio2.45
Capital Expenditure Coverage Ratio4.31
Dividend Paid and Capex Coverage Ratio4.31

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 9.24%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.11, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.61%, and total debt to capitalization, 10.10%, ratios shed light on its capital structure. An interest coverage of 21.37 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio9.24%
Debt Equity Ratio0.11
Long Term Debt to Capitalization3.61%
Total Debt to Capitalization10.10%
Interest Coverage21.37
Cash Flow to Debt Ratio1.63
Company Equity Multiplier1.22

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 49.73, provides a glimpse into top-line earnings distributed across each share. Net income per share, 21.04, reflects the portion of profit attributed to each share. The book value per share, 127.88, represents the net asset value distributed per share, while the tangible book value per share, 125.44, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share49.73
Net Income Per Share21.04
Book Value Per Share127.88
Tangible Book Value Per Share125.44
Shareholders Equity Per Share127.88
Interest Debt Per Share16.22
Capex Per Share-4.92

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 20.20%, indicates top-line expansion, while the gross profit growth, 15.67%, reveals profitability trends. EBIT growth, 20.95%, and operating income growth, 20.95%, offer insights into operational profitability progression. The net income growth, 35.40%, showcases bottom-line expansion, and the EPS growth, 31.66%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth20.20%
Gross Profit Growth15.67%
EBIT Growth20.95%
Operating Income Growth20.95%
Net Income Growth35.40%
EPS Growth31.66%
EPS Diluted Growth32.07%
Weighted Average Shares Growth2.86%
Weighted Average Shares Diluted Growth2.47%
Operating Cash Flow Growth21.87%
Free Cash Flow Growth12.64%
10-Year Revenue Growth per Share122.96%
5-Year Revenue Growth per Share32.90%
3-Year Revenue Growth per Share48.20%
10-Year Operating CF Growth per Share146.07%
5-Year Operating CF Growth per Share16.78%
3-Year Operating CF Growth per Share22.23%
10-Year Net Income Growth per Share503.65%
5-Year Net Income Growth per Share55.36%
3-Year Net Income Growth per Share80.67%
10-Year Shareholders Equity Growth per Share390.97%
5-Year Shareholders Equity Growth per Share99.48%
3-Year Shareholders Equity Growth per Share66.48%
Receivables Growth26.54%
Inventory Growth9.61%
Asset Growth18.57%
Book Value per Share Growth21.30%
Debt Growth-12.50%
R&D Expense Growth26.35%
SGA Expenses Growth-2.03%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 9,783,152,000, captures the company's total value, considering both debt and equity. Income quality, 0.99, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.17, gauges operational efficiency, while the research and development to revenue, 17.53%, highlights investment in innovation. The ratio of intangibles to total assets, 1.59%, indicates the value of non-physical assets, and capex to operating cash flow, -23.56%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value9,783,152,000
Income Quality0.99
Sales General and Administrative to Revenue0.17
Research and Development to Revenue17.53%
Intangibles to Total Assets1.59%
Capex to Operating Cash Flow-23.56%
Capex to Revenue-9.90%
Capex to Depreciation-433.08%
Stock-Based Compensation to Revenue1.68%
Graham Number246.06
Return on Tangible Assets13.96%
Graham Net Net44.38
Working Capital2,746,600,000
Tangible Asset Value5,870,600,000
Net Current Asset Value2,368,800,000
Average Receivables249,650,000
Average Payables4,850,000
Average Inventory106,900,000
Days Sales Outstanding44
Days Payables Outstanding8
Days of Inventory On Hand158
ROIC13.70%
ROE0.16%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.34, and the price to book ratio, 2.34, reflect the market's valuation relative to the company's book value. The price to sales ratio, 4.72, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 15.69, and price to operating cash flows, 12.76, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.34
Price to Book Ratio2.34
Price to Sales Ratio4.72
Price Cash Flow Ratio12.76
Price Earnings to Growth Ratio-0.10
Enterprise Value Multiple8.48
Price Fair Value2.34
Price to Operating Cash Flow Ratio12.76
Price to Free Cash Flows Ratio15.69
Price to Tangible Book Ratio1.72
Enterprise Value to Sales4.20
Enterprise Value Over EBITDA7.05
EV to Operating Cash Flow10.00
Earnings Yield9.57%
Free Cash Flow Yield7.26%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of United Therapeutics Corporation (UTHR) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 11.903 in 2024.

What is the ticker symbol of United Therapeutics Corporation stock?

The ticker symbol of United Therapeutics Corporation stock is UTHR.

What is company IPO date?

IPO date of United Therapeutics Corporation is 1999-06-17.

What is company current share price?

Current share price is 266.050 USD.

What is stock market cap today?

The market cap of stock today is 11803707325.000.

What is PEG ratio in 2024?

The current -0.101 is -0.101 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1168.